CA2940461A1 - Multi-component-multistage malaria vaccines - Google Patents

Multi-component-multistage malaria vaccines Download PDF

Info

Publication number
CA2940461A1
CA2940461A1 CA2940461A CA2940461A CA2940461A1 CA 2940461 A1 CA2940461 A1 CA 2940461A1 CA 2940461 A CA2940461 A CA 2940461A CA 2940461 A CA2940461 A CA 2940461A CA 2940461 A1 CA2940461 A1 CA 2940461A1
Authority
CA
Canada
Prior art keywords
seq
function
polypeptide
recombinant
mixture according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2940461A
Other languages
English (en)
French (fr)
Inventor
Alexander Boes
Holger Spiegel
Guven Edgu
Veronique Beiss
Markus Sack
Andreas Reimann
Rainer Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of CA2940461A1 publication Critical patent/CA2940461A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2940461A 2014-03-28 2015-03-27 Multi-component-multistage malaria vaccines Abandoned CA2940461A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461972002P 2014-03-28 2014-03-28
EP14001155.2 2014-03-28
US61/972,002 2014-03-28
EP14001155.2A EP2923709A1 (en) 2014-03-28 2014-03-28 Multi-component-multistage malaria vaccine
PCT/EP2015/056693 WO2015144874A1 (en) 2014-03-28 2015-03-27 Multi-component-multistage malaria vaccines

Publications (1)

Publication Number Publication Date
CA2940461A1 true CA2940461A1 (en) 2015-10-01

Family

ID=50396848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2940461A Abandoned CA2940461A1 (en) 2014-03-28 2015-03-27 Multi-component-multistage malaria vaccines

Country Status (5)

Country Link
US (1) US10183066B2 (https=)
EP (2) EP2923709A1 (https=)
JP (1) JP2017512498A (https=)
CA (1) CA2940461A1 (https=)
WO (1) WO2015144874A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
JP2020028219A (ja) * 2016-11-11 2020-02-27 大日本住友製薬株式会社 マラリアワクチン
US11273212B2 (en) 2016-11-11 2022-03-15 Sumitomo Dainippon Pharma Co., Ltd. Malaria vaccine
AU2018223223A1 (en) * 2017-02-27 2019-09-12 Expres2Ion Biotechnologies Aps A malaria vaccine and methods for producing same
US20180348218A1 (en) * 2017-06-05 2018-12-06 Tokitae Llc Serology assay for recent malaria infection
US11013791B2 (en) 2017-06-22 2021-05-25 The Government Of The United States, As Represented By The Secretary Of The Army NYVAC-based plasmodium malaria vaccine
WO2021060862A1 (ko) * 2019-09-24 2021-04-01 고려대학교 세종산학협력단 후코이단을 유효성분으로 포함하는 말라리아 예방 또는 치료용 약학적 조성물
EP4206225A4 (en) 2020-08-26 2024-10-02 National University Corporation Ehime University ANTI-MALARIA PARASITE ANTIBODIES
JP7649504B2 (ja) * 2022-02-18 2025-03-21 国立大学法人金沢大学 マラリアワクチン及びマラリア予防・治療方法
GB202301244D0 (en) * 2023-01-27 2023-03-15 Univ Oxford Innovation Ltd Vaccine
WO2024249116A1 (en) * 2023-05-26 2024-12-05 Seattle Children's Hospital D/B/A Seattle Children's Research Institute A multi-stage vaccine antigen for malaria
WO2025024337A1 (en) * 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US7488489B2 (en) * 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
AP2008004448A0 (en) * 2005-09-30 2008-04-30 Seattle Biomedical Res Inst Plasmodium liver stage antigens
EP2352751A2 (en) 2008-09-28 2011-08-10 Fraunhofer USA, Inc. Plasmodium vaccines, antigens, compositions and methods
US8444996B2 (en) 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
MX355501B (es) * 2010-09-27 2018-04-20 Inovio Pharmaceuticals Inc Star Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
US9422347B2 (en) * 2011-06-06 2016-08-23 The Regents Of The University Of California Algal produced malarial transmission blocking vaccines
CN102559613B (zh) * 2012-01-10 2014-04-23 特菲(天津)生物医药科技有限公司 一种恶性疟疾疫苗及其制备方法
DE102012013860A1 (de) 2012-07-05 2014-01-09 Thomas Dandekar DNA-arme Trypanosomen zur therapeutischen und diagnostischen Verwendung (DAT)

Also Published As

Publication number Publication date
US10183066B2 (en) 2019-01-22
JP2017512498A (ja) 2017-05-25
EP3122373A1 (en) 2017-02-01
US20170106071A1 (en) 2017-04-20
EP2923709A1 (en) 2015-09-30
WO2015144874A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
CA2940461A1 (en) Multi-component-multistage malaria vaccines
Hill et al. Prime-boost vectored malaria vaccines: progress and prospects
Duffy et al. Pre-erythrocytic malaria vaccines: identifying the targets
Carvalho et al. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects
Vekemans et al. Plasmodium falciparum malaria vaccines in development
US11857611B2 (en) Compositions and methods for generating an immune response to treat or prevent malaria
US10213501B2 (en) Three-component-multistage malaria vaccine
US9855321B2 (en) Vaccines against pregnancy-associated malaria
Dobaño et al. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity
Todryk et al. Building better T‐cell‐inducing malaria vaccines
ES2339765T3 (es) Cepas de mva recombinantes como vacunas potenciales contra la malaria por p. falciparum.
Miao et al. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines
CN103890004A (zh) 由具有特定免疫显性表位的婴儿利什曼虫pfr1蛋白片段组成的嵌合分子可用于抗利什曼病的免疫疗法
Da’dara et al. DNA vaccines against tropical parasitic diseases
Oliveira-Ferreira et al. Protective CD8+ T cell responses against the pre-erythrocytic stages of malaria parasites: an overview
US7981601B2 (en) Method of preparing polyepitope chimeric gene vaccine
US7749519B2 (en) Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax
US12502423B2 (en) Vaccine immunogens
Fischer et al. LLLLGGG GGGGGGG GGG LLL GGGGGG
Chowdhury et al. Malaria vaccine candidate diversity offers challenges and opportunities for effective vaccine development
ES2431613T3 (es) Vacunas contra la malaria basadas en virus recombinante
Boes et al. LLLLGGG GGGGGGG GGG LLL GGGGGG
Barclay et al. 7. Vaccine-induced strain specific immunity does not enhance competitive interactions between genetically diverse malaria parasites
Meerstein-Kessel et al. Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes
Dhanawat et al. Development in malarial vaccine: A review.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200122

FZDE Discontinued

Effective date: 20220519